MS Briefs

Impact of polypharmacy in RRMS


Key clinical point: Polypharmacy frequency can have a negative effect on relapsing-remitting multiple sclerosis (RRMS) patients.

Major finding: The proportion of polypharmacy among patients with a secondary illness to RRMS was four times higher than in patients without a secondary illness. Patients with polypharmacy were older, had a lower level of education, and had higher comorbidities than patients without polypharmacy.

Study details: Subgroups of 145 RRMS patients were analyzed. The subgroups were patients with polypharmacy, patients without polypharmacy, patients with secondary illness, and patients without secondary illness.

Disclosures: Michael Hecker support from Bayer HealthCare, Biogen, Novartis and Teva. Uwe Klaus Zettl received support from Almirall, Bayer HealthCare, Biogen, Merck Serono, Novartis, Sanofi and Teva. Niklas Frahm has no relevant conflicts of interest.

Citation: Frahm N, et al. PLoS One. 2019 Jan 24;14(1):e0211120. doi: 10.1371/journal.pone.0211120 .

Next Article: